Stockscreener 앱 받기
4.10
3.27%
0.13
시간 외 거래:
29.72
25.62
+624.88%
전일 마감가:
$3.97
열려 있는:
$3.97
하루 거래량:
687.47K
Relative Volume:
0.60
시가총액:
$300.67M
수익:
-
순이익/손실:
$-98.79M
주가수익비율:
-1.2538
EPS:
-3.27
순현금흐름:
$-51.66M
1주 성능:
+4.06%
1개월 성능:
-9.09%
6개월 성능:
+533.99%
1년 성능:
+1,023%
1일 변동 폭
$3.97
$4.18
1주일 범위
$3.70
$4.53
52주 변동 폭
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.72 | 5.73B | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
8.66 | 453.72M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.43 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
2.855 | 252.54M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DWLD
Davis Select Worldwide ETF
|
47.16 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-23 | 재개 | Leerink Partners | Outperform |
| 2025-12-22 | 개시 | Jefferies | Buy |
| 2025-11-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
How do insiders feel about Relmada Therapeutics Inc.Quarterly Growth Report & Fast Entry High Yield Stock Tips - mfd.ru
Leerink Partners Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $8 - 富途牛牛
Leerink Partners Upgrades Relmada Therapeutics (RLMD) - Nasdaq
Leerink Partners upgrades Relmada stock to Outperform on bladder cancer treatment potential By Investing.com - Investing.com Nigeria
Leerink Partners upgrades Relmada stock to Outperform on bladder cancer treatment potential - Investing.com Nigeria
Relmada Therapeutics (NASDAQ:RLMD) Upgraded by Leerink Partners to Outperform Rating - MarketBeat
Relmada Therapeutics (RLMD) Upgraded by Leerink Partners to 'Out - GuruFocus
Targets Report: Is now the right time to enter Relmada Therapeutics IncMarket Risk Analysis & Reliable Price Breakout Alerts - baoquankhu1.vn
Tech Rally: Does Relmada Therapeutics Inc meet Warren Buffetts criteria2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Bull Run: Is Relmada Therapeutics Inc in accumulation or distribution phase2025 Growth vs Value & Detailed Earnings Play Strategies - baoquankhu1.vn
Relmada’s New Phase 3 Bladder Cancer Trial Adds a Fresh Catalyst to Its Pipeline - TipRanks
FDA endorses Relmada’s registrational strategy for bladder cancer therapy - Indian Pharma Post
Is Relmada Therapeutics Inc stock affected by interest rate hikesWeekly Trend Summary & High Win Rate Trade Tips - Bộ Nội Vụ
Relmada’s BOOST phase 3 bladder cancer trial sets up a new catalyst for RLMD investors - MSN
Relmada receives FDA feedback for bladder cancer therapy trials By Investing.com - Investing.com Canada
Will Relmada Therapeutics Inc. (4E2) stock outperform energy sector in 2025Footwear buying guidance for all day wear during busy schedules focuses on foot fatigue reduction, making it helpful for judging overall value. - ulpravda.ru
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - Investing News Network
Relmada Therapeutics (RLMD) Advances NDV-01 with FDA Guidance - GuruFocus
Relmada gets FDA alignment on NDV-01 bladder cancer trial designs - StreetInsider
FDA backs new bladder cancer studies for patients with few options left - Stock Titan
Will Relmada Therapeutics Inc. stock benefit from infrastructure spendingForecast Cut & Low Risk High Reward Ideas - Улправда
How supply chain issues affect Relmada Therapeutics Inc. stockBuy Signal & Weekly Momentum Stock Picks - ulpravda.ru
Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Corient Private Wealth LLC Invests $120,000 in Relmada Therapeutics, Inc. $RLMD - Defense World
Small Cap Biotech In 2025: Winning Pivots And Zombie Killers - Citeline News & Insights
Relmada’s BOOST Phase 3 Bladder Cancer Trial Sets Up a New Catalyst for RLMD Investors - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update - Defense World
Jefferies Financial Group Begins Coverage on Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage of Relmada Therapeutics (RLMD) with Buy Recommendation - Nasdaq
Relmada Therapeutics (RLMD) Initiates Coverage with Buy Rating | RLMD Stock News - GuruFocus
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Treasury Yields: Is NEHC stock recession proof2025 Trading Recap & Weekly Stock Breakout Alerts - moha.gov.vn
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot - Investing.com
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot By Investing.com - Investing.com South Africa
Jefferies Starts Relmada Therapeutics Inc (RLMD) at Buy - StreetInsider
Inflation Data: Will Las Vegas Sands Corp stock outperform value peersPortfolio Return Summary & Real-Time Market Sentiment Reports - moha.gov.vn
Is Relmada Therapeutics Inc. stock supported by strong cash flowsPortfolio Growth Summary & Entry Point Confirmation Alerts - Улправда
Why Relmada Therapeutics Inc. stock remains undervalued2025 Buyback Activity & Real-Time Buy Zone Alerts - Улправда
Momentum Shift: Why Relmada Therapeutics Inc. (4E2) stock benefits from AI revolution2025 Performance Recap & Low Risk Growth Stock Ideas - Улправда
Recap Report: Is Relmada Therapeutics Inc. stock supported by strong cash flowsBond Market & AI Enhanced Trading Alerts - Улправда
How Relmada Therapeutics Inc. (4E2) stock moves in volatile trading sessions2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
Is Relmada Therapeutics Inc. stock supported by innovation pipeline2025 Market Trends & Reliable Intraday Trade Alerts - Улправда
Have you been able to find a good deal on Relmada Therapeutics Inc’s shares? - uspostnews.com
RelmadaA New Contender To Watch In Bladder Cancer Drug Development? - RTTNews
Maged Shenouda Increases Stake in Relmada Therapeutics Inc (RLMD) - GuruFocus
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):